The vasodilatory effects of hydralazine, nicardipine, nitroglycerin, and fenoldopam in the human umbilical artery

Anesthesia and Analgesia

Volumn 96, Issue 2, 2003, Pages 539-544

  Sato, Nobukazu ^c   Tanaka, Kenichi A ^c   Szlam, Fania ^c   Tsuda, Atsushi ^c   Arias, Maria E ^a   Levy, Jerrold H ^b  

^a Atlanta Women's Specialists   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; NICARDIPINE; PHENOXYBENZAMINE; POTASSIUM CHLORIDE; PRAZOSIN; THROMBOXANE A2 DERIVATIVE; VASODILATOR AGENT;

ARTICLE; BLOOD FLOW VELOCITY; CONCENTRATION RESPONSE; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; HUMAN TISSUE; MATERNAL HYPERTENSION; PREGNANCY; PRIORITY JOURNAL; UMBILICAL ARTERY; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENOLDOPAM; HUMANS; HYDRALAZINE; MUSCLE CONTRACTION; NICARDIPINE; NITROGLYCERIN; POTASSIUM CHLORIDE; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, ADRENERGIC, ALPHA; THROMBOXANE A2; UMBILICAL ARTERIES; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0346221412     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200302000-00044     Document Type: Article

References (25)

1. 2 and their ratio in normotensive and preeclamptic pregnant women during the antepartum and postpartum periods. Matern Fetal Med 2000;9: 173-7.
2. Woods LL. Importance of prostaglandins in hypertension dur ing reduced uteroplacental perfusion pressure. Am J Physiol 1989;257:R1558-61.
3. Gudmundsson S, Gennser G, Marsal K. Effects of hydralazine on placental and renal circulation in pre-eclampsia. Acta Obstet Gynecol Scand 1995;74:415-8.
4. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol 1994;84:354-9.
5. Giles W, O'Callaghan S, Boura A, Walters W. Reduction in human fetal umbilical-placental vascular resistance by glyceryl trinitrate. Lancet 1992;340:856.
6. Gerstner G, Grunberger W. Dopamine treatment for the prevention of renal failure in patients with severe eclampsia. Clin Exp Obstet Gynecol 1980;7:219-22.
7. Kirshon B, Lee W, Mauer MB, Cotton DB. Effects of low dose dopamine therapy in the oliguric patient with preeclampsia. Am J Obstet Gynecol 1988;159:604-7.
8. Grunberger W, Szalay S. Uterine and systemic vascular responses to dopamine in pregnant ewes. Arch Gynecol 1983;233: 259-62.
9. Ferreira-de-Almeida JA, Pereira-Leite L, Cavallotti C, et al. Pharmacological characterization and autoradiographic localization of dopamine D1 receptors in the human umbilical artery. Eur J Pharmacol 1993;234:209-14.
10. Belfort MA, Saade GR, Suresh M, et al. Human umbilical vessels: responses to agents frequently used in obstetric patients. Am J Obstet Gynecol 1995;172:1395-1402.
11. Rhee HM, Song BJ, Cushman S, Shoaf SE. Vascular reactivity in alcoholic rat aortas: in vitro interaction between catecholamines and alcohol. Neurotoxicology 1995;16:179-85.
12. Harrison WE, Mellor AJ, Clark J, Singer DRJ. Vasodilator pretreatment of human radial arteries: comparison of effects of phenoxybenzamine vs papaverine on norepinephrine-induced contraction in vitro. Eur Heart J 2001;22:2209-16.
13. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993;87:1461-7.
14. David M, Halle H, Lichtenegger W, et al. Nitroglycerin to facilitate fetal extraction during cesarean delivery. Obstet Gynecol 1998;91:119-24.
15. Harper A, Murnaghan GA. Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. Br J Obstet Gynaecol 1991; 98:453-9.
16. Khedun SM, Moodley J, Naicker T, Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther 1997;74:221-58.
17. Carbonne B, Jannet D, Touboul C, et al. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol 1993;81: 908-14.
18. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 1990;81:970-7.
19. Gombotz H, Plaza J, Mahla E, et al. DA1-receptor stimulation by fenoldopam in the treatment of postca rdiac surgical hypertension. Acta Anaesthesiol Scand 1998;42:834-40.
20. Bodelsson G, Stjernquist M. Characterization of contractile adrenoceptors in the human umbilical artery. Eur J Pharmacol 1995;282:95-101.
21. Nakamura S, Kohli JD, Rajfer SI. Alpha-adrenoceptor blocking activity of fenoldopam (SK&F 82526), a selective DA1 agonist. J Pharm Pharmacol 1986;38:113-7.
22. Ohlstein EH, Zabko-Potapovich B, Berkowitz BA. The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist. Eur J Pharmacol 1985;118:321-9.
23. Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001;285: 1607-12.
24. Berdeaux A, Ghaleh B, Dubois-Rande JL, et al. Role of vascular endothelium in exercise-induced dilation of large epicardial coronary arteries in conscious dogs. Circulation 1994;89: 2799-808.
25. Ghaleh B, Dubois-Rande JL, Hittinger L, et al. Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br J Pharmacol 1995;114:496-502.